Fortune September 23, 2020
A coronavirus vaccine won’t be a silver bullet against the COVID pandemic, but public health experts say it’s an important step that could start the process of a return to normalcy. And four companies (alongside their partners) are vying for first-to-market entry with late-stage trials underway.
Firms ranging from pharmaceutical giants to startup biotechs—in the U.S. and abroad—are all part of this race. But the regulatory process can be a labyrinth, and the fundamental question of scientific accuracy for a vaccine that will ostensibly be distributed to hundreds of millions of people is critical.
“The FDA will not authorize or approve a vaccine we won’t be confident in giving to our families,” said Food and Drug Administration (FDA) commissioner Stephen...